interferon-ineligible/intolerant individuals, supporting the AASLD/IDSA guidance and offering implications for both clinical and regulatory decision-making as well as pharmaceutical pricing.
Newly approved direct-acting antiviral agents for chronic hepatitis C (CHC) have increased rates of sustained virologic response (SVR) to unprecedented levels, curing more than 90% of infections in many subgroups without the need for interferon (1).
However, individuals with genotype 1 infection remain more difficult to treat, and both clinical guidelines and Food and Drug Administration approvals call for continued use of interferon alongside direct-acting antivirals sofosbuvir or simeprevir for this group (2-4).
In some populations, up to 56% of those with CHC are ineligible to receive interferonbased treatment due to medical or psychological comorbidities, substance abuse, or prior treatment failure (5, 6). For these people, there are currently two interferon-free treatment options available in some regions: sofosbuvir plus ribavirin (SOF/RBV) for 24 weeks, which yields SVR rates between 52% and 84% at a cost of approximately US$169,000 (7-12), and sofosbuvir plus simeprevir (SOF/SMV) for 12 weeks, with SVR rates ranging from 89-100% at a cost of $150,000 (13, 14) . Although treatment with SOF/SMV is more effective, less costly, and of shorter duration compared to SOF/RBV, it has not yet been specifically approved for clinical use by the US Food and Drug Administration, resulting in debate among both physicians and payers about whether it should be prescribed and reimbursed. This analysis compares the long-term costeffectiveness of these two treatment strategies.
Methods

Markov Model
Using TreeAge Pro 2013 software (TreeAge Software, Inc., Williamstown, MA, USA), we constructed a decision-analytic Markov model to simulate the progression of a 50- 
Cohort age was chosen based on estimates that US hepatitis C virus (HCV)
seroprevalence peaks in the 50-59 age group (15) . The model cohort reflects both treatment-naïve and treatment-experienced subjects, with the exception of those who have failed prior telaprevir/boceprevir-based treatment and may harbor HCV variants resistant to HCV protease inhibitors including simeprevir.
The decision tree that underlies the Markov model is presented in Figure 2 . Parameters representing CHC natural history, treatment, treatment outcomes, and re-treatment determined subjects' pathways through the decision tree. Base case values for all model parameters and ranges used in sensitivity analyses are listed in Tables 2-6. At the end of each model year (stage), subjects accrued the costs and quality-adjusted life years (QALYs) associated with their disease state and treatment status during that year. Death was possible from any model stage. Subjects alive at the end of a given stage continued progressing through the model as determined by their disease state or treatment outcome in the preceding year, and they continued accumulating costs and QALYs each year until death. Analysis terminated when the cohort reached its average life expectancy. Cumulatively, the costs and QALYs accrued by the subjects in each treatment branch were used to calculate the incremental cost-effectiveness ratio (ICER). Cumulative costs were used to calculate the cost per SVR under each treatment strategy. Costs considered in this analysis include the direct costs of 
Measures
To assess cost-effectiveness, we calculated the ICER, which measures the incremental cost of the more effective treatment strategy per QALY it adds to the average subject's lifespan, compared to the less effective treatment strategy. We also calculated cost savings per SVR under the dominant treatment strategy. We conducted one-way sensitivity analyses to determine whether variation in key model parameters impacted the ICER or the cost per SVR, including sub-analyses exploring differences by viral genotype (1a vs. 1b) and Q80K status.
Background Mortality Rates
Age-specific background mortality rates were applied throughout the model. Before SVR, they were set at 2.37 times the mortality rates for individuals without CHC (16, 17) . After SVR, subjects were assigned lower mortality rates, set at 1.4 times non-CHC rates, based on evidence that viral clearance improves overall health outcomes (Table   2 ) (18) . Subjects with end-stage liver disease were assigned higher mortality rates based on published literature (Table 3) .
Genotype 1a vs. 1b and Q80K Polymorphism
Q80K is a naturally occurring polymorphism found in up to 47% of those infected with HCV genotype 1/subtype A, and its presence has been associated with lower SVR rates among individuals treated with simeprevir in combination with other drugs (19, 20) . In the SOF/SMV treatment arm of this model, genotype 1a outcomes were stratified by Q80K status to reflect lower SVR rates among Q80K+ subjects, and Q80K screening was included in treatment costs associated with SOF/SMV treatment. Variation in the proportion of Q80K+ individuals was explored in sensitivity analyses. In the SOF/RBV arm, genotypes 1a and 1b were collapsed, Q80K status was not incorporated into the model structure, and Q80K testing was not included in treatment-associated costs.
Fibrosis Stages
Probability of SVR was dependent on fibrosis stage, defined by METAVIR score (F0 = no fibrosis; F1 = portal fibrosis without septa; F2 = portal fibrosis with few septa; F3 = numerous septa without cirrhosis; F4 = compensated cirrhosis) (21) . Cost of noninvasive fibrosis staging was included in the analysis for both treatment arms. Initial distribution of subjects across fibrosis stages and annual progression probabilities to later stages are listed in Tables 2-3. The model did not include subjects with decompensated cirrhosis due to uncertainty regarding treatment tolerance. To reflect the possibility that individuals with early stage fibrosis may elect to postpone treatment, sensitivity analyses include a scenario under which only subjects with advanced fibrosis (stages F3-F4) are treated.
To account for evidence of liver regeneration after viral eradication, the model allowed post-SVR fibrosis regression according to probabilities from published literature (Table   4 ) (22) (23) (24) (25) (26) . When a disease state transition occurred (e.g., progression from F0 to F1 
Re-treatment
To reflect clinical expectations, most subjects not cured with initial treatment (SOF/SMV or SOF/RBV) were re-treated with rescue therapy. The percentage re-treated was assumed to be 90% for base case analysis and was varied in sensitivity analyses (Table 4) . Sofosbuvir plus ledipasvir for 24 weeks (SOF/LDV) was chosen as the rescue therapy drug regimen for this model, based on its estimated availability in 2014 and its very high SVR rates in clinical trials (95-100%) (27) Further, since LDV is an inhibitor of HCV NS5A, this agent is expected to be effective in individuals who failed prior treatment that included HCV NS3/4A protease inhibitors such as SMV. The base case cost of SOF/LDV was set at 1.5 times the cost of sofosbuvir alone for 24 weeks, with a range extending from $0 to 2 times the cost of sofosbuvir (Table 6 ). QALYs associated with SOF/LDV rescue therapy were set equal to QALY estimates for SOF/SMV treatment due to the absence of ribavirin in both regimens. The rate of possible reinfection after viral clearance was assumed equal for both treatment arms and was not included in the model structure.
Treatment-related Medical Care
Both SOF/RBV and SOF/SMV treatment strategies included the costs of initial HCV screening, a new patient visit, genotype assay, and non-invasive fibrosis staging The model also includes the cost of treatment-related adverse events, identified from published prescribing information and clinical trial data for the relevant drug regimens.
Costs of adverse events were weighted based on estimated incidence of each event (3, 4, 27).
Costs and QALYs
Most medical costs and QALYs were derived from two recent cost-effectiveness studies that provide comprehensive reviews of these parameters from a variety of published sources (Tables 5-6 ) (28, 29) . Costs to manage treatment-related adverse events were obtained from the Department of Veterans Affairs National Acquisition Center database (12) . Costs were adjusted to 2013 US dollars, and both costs and QALYs were discounted 3% per year.
QALY values associated with interferon-free treatments have not yet been published due to the short amount of time since US Food and Drug Administration approval. For these parameters, we used treatment-related QALY values generated in a previous cost-effectiveness study based on expert opinion (30) . Due to the uncertainty of these values, sensitivity analyses involving QALY parameters incorporated ranges of ±10%.
Because these QALY estimates refer to an all-oral regimen that included ribavirin, we increased them slightly in the SOF/SMV and SOF/LDV regimens in the present analysis to reflect a reduction in adverse events without ribavirin (Table 5 ). This decision is
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Hepatology Hepatology supported by placebo-controlled trials of SOF/RBV, in which subjects in the active treatment group experienced greater incidence of hemolytic anemia, insomnia, fatigue, and cough compared to the placebo group (4). Documented photosensitivity and increased bilirubin associated with simeprevir were not deemed severe enough to counteract the absence of ribavirin in terms of quality of life measures during treatment with SOF/SMV. Likelihood of adverse events was doubled in sensitivity analyses.
Drug interactions between sofosbuvir and simeprevir are not expected due to differing modes of metabolism (renal vs. hepatic), and published prescribing information for these drugs indicates minimal interactions with other medications (3, 4). Therefore, drug-drug interactions were not included in related quality of life measures or treatment costs, though we expect that on an individual level, clinicians will consider concurrent medications in decisions regarding eligibility for treatment with SOF/SMV or SOF/RBV.
Results
Base Case Analysis
In the base case scenario, SOF/SMV dominated SOF/RBV. Over the duration of the model, the SOF/SMV regimen yielded lower costs and more quality-adjusted life years (Table 1) .
Sensitivity Analyses
We conducted sensitivity analyses among subgroups that have experienced lower SVR rates with SOF/SMV treatment in clinical trials (genotype 1a, Q80K+ subjects only), as well as those who have shown greater incidence of adverse events with both regimens (F3 and F4 subjects only). Additional parameters that were varied in sensitivity analyses included the proportion of subjects in all fibrosis stages experiencing treatment-related adverse events, cost of SOF/LDV rescue therapy for those who fail to achieve SVR with initial treatment with SOF/RBV or SOF/SMV, SVR rates for SOF/SMV, SOF/RBV, and SOF/LDV regimens, and proportion of subjects re-treated with SOF/LDV rescue therapy after initial treatment failure. Under all scenarios tested, the SOF/SMV treatment strategy remained dominant and resulted in cost savings per SVR compared to SOF/RBV (Table 1) .
Discussion
The initial approval of sofosbuvir was limited to its use with ribavirin, with or without peginterferon, and the approval of simeprevir was limited to a combination with both ribavirin and peginterferon. As a result, some clinicians face reimbursement barriers when prescribing SOF/SMV together because it is not a specifically approved (13) . Further, the sample sizes in some cited trials are relatively small, contributing to parameter uncertainty with respect to the expected SVR rates with these regimens (e.g., n = 167 in the COSMOS study for SOF/SMV, and n = 114 and n = 60 in the PHOTON-1 and SPARE studies for SOF/RBV, respectively) (9, 10, 13). CHC natural history after treatment with these specific drug regimens is also uncertain, as is the specific distribution of fibrosis stages among genotype 1 interferon ineligible/intolerant individuals (assumed in this analysis to mirror the fibrosis distribution in the general population with CHC). Sensitivity analyses were included to model these uncertainties in SVR and natural history parameters; in each of these models, treatment with SOF/SMV remained dominant.
The cost of a SOF/LDV regimen is not yet known and is modeled under a wide range in sensitivity analyses. QALY estimates for treatment with interferon-free regimens are not available in published literature, thus quality of life studies specific to these treatment regimens are warranted. In addition, this model does not account for the possibility of reinfection after SVR, nor for the population benefit of preventing incident HCV infections through reductions in the pool of infected individuals. This analysis considers direct medical costs only and does not reflect indirect costs such as productivity losses attributable to CHC. Some of these limitations could result in over-estimation of cost savings (i.e., high SVR rates and absence of re-infection probabilities), while others could contribute to estimates that are more conservative (i.e., absence of indirect costs and the prevention benefit of infections cured).
While these potential limitations warrant careful consideration, this analysis offers evidence that the ability of SOF/SMV to cure a greater number of individuals and to reduce the need for re-treatment can be expected to result in lower immediate and longterm costs to payers as well as better outcomes for individuals compared to SOF/RBV.
Combined with its potential for improved tolerability in the absence of ribavirin, shorter treatment duration, and higher resulting adherence to treatment, the economic dominance of SOF/SMV can contribute to the debate regarding its reimbursement.
In this analysis, SOF/SMV continued to yield cost savings per SVR when the cost of SOF/LDV rescue therapy was set to zero. Thus, even if the cost of re-treatment for Table 4 for low and high SVR thresholds for each drug regimen, and for low threshold for proportion retreated after initial failure. F3/F4 = Metavir fibrosis stages 3 and 4; LDV = ledipasvir; RBV = ribavirin; SMV = simeprevir; SOF = sofosbuvir; SVR = sustained virologic response; Q80K = a naturally occurring polymorphism found in up to 47% of HCV genotype 1/subtype A infected individuals and less commonly in those with HCV genotype 1/subtype B; the presence of this polymorphism has been associated with lower SVR rates in subjects treated with simeprevir in combination with other drugs. 
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